19. Van The importance of measuring creatinekinase-MB (CK-MB, CK2, variant of ATP:creatine N-phosphotransferase, EC 2.7.3.2) as a diagnostic aid in identification of myocardial infarction has been well established.4 CK-MB is routinely measured in clinical chemistry laboratories worldwide by many methods, which vary in specificity, sensitivity, and precision (1-7). We recentlypublished a method for the direct assay of CK-MB activity in serum based on the use of a unique monoclonal antibody ("Conan-MB") immobilized on latex particles 0.8 pin in diameter (8). The CK-MB was immunoextracted from diluted serum samples, the latex beads were washed and separated by centriftigation, and then the catalytic activity of the bound CK-MB was measured. Although this assay was highly specific, manipulation of the latex particles was tedious, and precision was less than optimal.
precision (1) (2) (3) (4) (5) (6) (7) . We recentlypublished a method for the direct assay of CK-MB activity in serum based on the use of a unique monoclonal antibody ("Conan-MB") immobilized on latex particles 0.8 pin in diameter (8). The CK-MB was immunoextracted from diluted serum samples, the latex beads were washed and separated by centriftigation, and then the catalytic activity of the bound CK-MB was measured. Although this assay was highly specific, manipulation of the latex particles was tedious, and precision was less than optimal.
We describe here our modifications of the assay that have made it suitable for routine laboratory use. The improvements include use of 0.64-cm (diameter) beads as solid support for the immobilization of antibody, use of undiluted serum, termination of the enzyme catalytic reaction by the addition of CDTA to chelate Mg2, and the development of a colored product to increase the signallnoise ratio. The entire assay was semiautomated on commercially available equipment. We have monitored the performance of the assay in routine clinical use and compared results with those by a CK-MB mass assay and by electrophoresis.
Materials and Methods
Coating Beads with CK-MB-Specific Antibody Production, characterization, and purification of a monoclonal antibody specific for CK-MB (Conan-MB) have been described previously (8).
The polystyrene beads (0.64-cm in diameter, with specular finish) were from Precision Plastic Ball Co., Chicago, IL 60641. We coated them with Conan-MB by passive adsorption. Ten thousand beads were washed five times with distilled water and once with 0.1 mol/L sodium phosphate, pH 6 .0 (coating buffer). The beads were then covered with 1200 mL of a 42-50 mg/L solution of Conan-MB in coating buffer and incubated for 24-40 h at 4#{176}C, with occasional stirring.
We removed the coating solution from the beads and assayed it for remaining protein by the method of Bradford (9), using the Bio-Rad Protein Assay Kit (Bio-Rad Labs., Richmond, CA 94804). To calculate the density of the antibody coated onto the beads, we multiplied the percent of protein bound to the beads by the original amount of protein and divided by the number of beads. Uncoated sites on the beads were blocked by incubation for 4 h at room temperatare (or overnight at 4 #{176}C) with Ths-buffered saline (TBS; 50 mniol of Tris, pH 7.2, and 150 mmol of NaC1 per liter) 
Samples, Standards, and Quality-Control Material
Serum samples submitted to the Barnes Hospital or Jewish Hospital chemistry laboratories for analysis of CK-MB were stored at 4#{176}C and assayed within 24 h. f3-Mercaptoethanol (final concentration, 15 mmol/L) was added to serum at Barnes Hospital immediately after separation from cells. Standards were prepared by adding purified CK-MB (10) to a serum pool that had been inactivated by heating at 56#{176}C for 45 mm (heat-inactivated serum pool, HISP) and supplemented with 10 mmol of /3-mercaptoethanol per liter. The value for the highest standard (S4) was assigned as 109 U/L after repeated assays for total CK based on a modified procedure of Rosalki (11) at 37 #{176}C in a Flexigemtm centrifugal analyzer and with the manufacturer's reagent (Electro-Nucleonics Inc., Fairfield, NJ 07006). Threefold serial dilutions of S4 in HISP produced standards with CK-MB activities ranging from 4 to 109 U/L. Standards were divided into 0.5-mL aliquots and stored at -70 #{176}C. Quality-control materials were prepared similarly to give CK-MB values of approximately 10 UIL and 50 UIL and stored in 1-mL aliquots.
Reagents
Creatine kinase reagent. The CK reagent used in the routine assay was prepared weekly by the chemistrylaboratory of Jewish Hospital and stored at 4#{176}C. The 
Alternative CK-MB Assays
We assayed 639 consecutive serum samples from Barnes Hospital by both the direct colorimetric assay as described above and by EnzygnostTM CK-MB assay (BehringDiagnostics), a two-site immunoenzymometric assay for measuring the mass of CK-MB; we followed the manufacturer's procedure.
Over a six-month period, 347 serum samples with CK-MB values 12 U/L by the direct colorimetric assay were also assayed by an agarose electrophoresis method in which the activity of CK isoenzymes is measured semiquantitatively 
Analytical Variables
In this paper we use the term "total imprecision" to refer to assay-to-assay imprecision, which is a combination of the independent components of "within-assay imprecision" and "between-assay imprecision" (12, 13). Total assay imprecision of assaying the quality-control materials was calculated over a five-month period at Barnes Hospital and over a four-month period at Jewish Hospital. We estimated the components of within-and between-assay imprecision of quality-control material and serum samples,run in duplicate, from an analysis of variance for a hierarchical design with unequal replication (14).
Analytical-recovery studies were performed by adding 10 iL of HISP containing CK-MB-0 (control), 109, or 591 U/ L-to 100 ,.&L of patients' samples with endogenous CK-MB activities of approximately 10 U/L. The CK-MB activity was then measured in the direct assay. Analytical recovery was calculated by the following formula:
We also assessed recovery by adding CK-MB to three lipemic samples with triglyceride concentrations of 16.6, 27.3, and 36.0 g/L to an icteric sample containing 0.52 g of bilirubin per liter, and also to an hemolysate containing 7 g of hemoglobin per liter.
Potential interference from high concentrations of other CK isoenzymes was assessed by assaying HISP supplemented with CK-MB (26 U/L) with or without addition of CK-MM (15) or CK-BB (Calbiochem Behring Diagnostics, San Diego, CA92112) at values ranging from 0 to 92500 UIL.
Results

Optimization of Assay
We evaluated the utility of polyamide, polystyrene, and hydrazide beads, using the following techniques: passive adsorptionbefore or after mild acid hydrolysis; covalent linkage via glutaraldehyde or carbodiimide bridges; activation by nitration followed by reduction and diazotization (16); linkage to commercially available hydrazide beads (Pierce Chemical Co., Rockford, IL 61103) directly according to the manufacturers protocol or via protein A or goat antimouse-Fc antibody bridges. We assessed these different preparations by two criteria: (a) The mass of antibody adsorbed or bound to the beads was monitored by adding 'I-labeled Conan-MB to coating solutions and measuring the radioactivity associated with the beads after washing. (b) The amount of CK-MB extracted from solution by immobilized Conan-MB was determined by measuring both the amount of CK-MB enzymatic activity associated with the beads and the amount of activity remaining in solution. Monitored for 0-4 h, the extraction of CK-MB from solution was maximal after 2 h with all bead preparations, although the absolute amount of CK-MB extracted varied ( Table 1) . The amount of CK-MB activity extracted and that left in solution were reciprocal (data not shown), indicating that all CK-MB activity was accounted for.
The technique of passive adsorption to polystyrene beads produced the best extraction results (Table 1) . Although under one condition we were able to covalently link 40 ig of Conan-MB onto a single bead, the amount and time course of CK-MB extraction with this preparation were not better than that attained with polystyrene beads with 2.5 zg of passively adsorbed antibody per bead. In fact, in most cases, ,,,,, was monitored at 37 #{176}C covalent linkage led to immobilization of larger amounts of antibody, but the ability of the immobilized antibody to bind CK-MB was decreased, possibly owing to steric hindrance or inter-or intra-molecularcross-linking of the antibody molecules themselves.
The passive adsorption of antibody to polystyrene beads appeared essentially irreversible. More than 95% of 'Ilabeled Conan-MB initially bound remained attachedafter the extractionand washing steps of the assay. In addition, we electrophoresed serum supplemented with CK-MB (110 U/L) and incubatedwith Conan-MB, either in solution or passivelyadsorbed to polystyrene beads. The serum exposed to the passively adsorbed Conan-MB showed no evidence of a CK-MB--antibody complex, although one was clearly visible when Conan-MB equal to 1% of that passively adsorbed was added in solution. After determining the coating technique, we optimized the coating density. Although at least 6.5 g of Conan-MB could be passively adsorbed to each bead, there was no increase in signal in the direct assay at amounts >1.5 g per bead (Figure 1) . We now routinely coat the beads with 5 of antibody per bead; the resulting coating density is 2-3 g per bead. Agitating the beads or recirculating the coating solution did not seem to increase the adsorption of antibody or improve the performance of the coated beads (data not shown).
In developing this assay, we initially used commercial CK reagent (Electro-Nucleonics) and monitored the NADH concentration at 340 nm. For the extraction step we used 60-well reaction trays [Abbott Laboratories; 12 X 30 X 2.5 cm, with 0.8-cm (i.d.) round-bottomed wells], which allowed use of available bead-washing equipment. One-hundred microliters of serum suffices to cover the beads. With constant shaking at room temperature, the extraction of CK-MB is essentially complete after 1 h (Figure 2 ). Approximately half of the CK-MB is extracted from serum under these conditions, and the extraction efficiency is constant over a wide range of CK-MB activities (data not shown).
In our previous assay we stopped the catalytic reaction at the end of the 37 #{176}C incubation by chilling the reaction mixtures and centrifuging to remove the latex particles. We have simplified this step by instead adding a solution that stops the enzymatic reaction (Figure 3) by chelating magnesium, which is required for CK enzymatic activity (2). The stopping solution contains Tris buffer, pH 7.5, and CDTA, which has an extremely high affinity for magnesium at this pH (17). The ,,,, after the addition of CDTA at concentrations of 4 mmoVL or greater was 0.00 14/mm.
We developed a colored end product so we could use available colorimeters and could enhance the signal/noise ratio. The tetrazolium dye, INT, is reduced to its colored formazan in the presence of NADH and an electron carrier (18). The reduced form of INT has an absorptivity of 1940 L x mol' x mm1 at 492 nm, which is approximately threefold higher than that of NADH at 340 nm. We originally We tested diaphorase as the electron carrier and found it more suitable. We optimized the concentrations of diaphorase and INT (Figure 4) and combined the stopping and color reagents in a single solution. The color development is complete within 2 mm and the color is stable for several hours without removal of the beads (data not shown). The assay curve is linear to 200 U/L CK-MB ( Figure 5 ) and the absorbance of the 12-U/L standard is threefold greater than background.
We have tested this system for feasibility in a kinetic assay by combining INT and diaphorase or phenazine methosulfate with the CK reagent in the enzymatic step. In these experiments there was very little color development over 30 mm at 37 #{176}C. We therefore utilizedthe reagents in two steps as described.
We prepared CK reagent without sulthydryl activatorto prevent non-enzymaticreduction of INT (18). To ensure that CK-MB in serum samples was activated, we included 1 to 100 mmol of -mercaptoethanol per liter in the extraction step of the assay. The measured CK-MBactivities were identical at all concentrations of -mercaptoethanol and equal to that found by using a commercial CK reagent containing sulihydryl activator. The same samples assayed without (3-mercaptoethanol had substantially decreased CK-MB activity (data not shown). We therefore add 20 mmol of 13-mercaptoethanol per liter to each sample.
Assay Performance
Nine 10000-bead lotswere prepared with an average coating density of 2.25 ug of Conan-MB per bead. We observed no difference in performance between any of the lots, and the coated beads could be used for at least eight months. The total imprecision over a five-or four-month period at Barnes or Jewish Hospitals was 14.1% and 16.8% for the lower concentration of quality-control material and 11.6% and 14.8% at the higher concentration (Table 3) . We assessedthe within-assay and between-assay contribution to the total assay variance and compared the imprecision of quality-control materials to that of patients' samples at Barnes Hospital. The larger component of imprecision was within-assay except for the patient group with CK-MB values >110 U/L, all of which were assayed after dilution. Dilution error could account for the higher between-assay component of imprecision of this group. The precision for patients' sampleswas found to be comparable to that for the quality-control materials.
Results of the direct routine assay compared well with UfL two days later. CK-MB as measured by another laboratory was 6 UIL for a sample obtained 11 h after the sample that gave us the increased value. Lactate dehydrogenase isoenzyme 1:2 ratios were 0.4-0.7 before and after the increased CK-MB. The patient had major abdominal surgery two days before the elevated CK-MB value and had a history of coronary artery disease, confirmed by cardiac catherization. She was transferred to the cardiac-care unit on the day the sample with increased CK was obtained, where she was treated for myocardial infarction. She had additional episodes of chest pain two days after the admission to the cardiac-care unit.
Discussion
CK-MB is measured in >25000 samples per year at the clinical chemistry laboratories of Barnes and Jewish Hospitals. Most recently CK-MB had been quantified by use of Behring's Enzygnost#{176}' assay kits. Some problems with this assay had developed (19) and the test was subsequently removed from the market. We evaluated several alternative commercial assays but failed to find a suitable substitute. We therefore modified a previously developed assay based on our monoclonal antibody to CK-MB (8) to make it suitable for routine laboratory use.
We believed that both precision and ease of handling could be improved by immobilization of Conan-MB onto larger beads than we had previously used. The availability of paoqumm and Pentawash II bead-washing systems led us to utilize 0.64-cm beads. Likewise, the available spectrophotometers required larger final volumes for measurement than our previous assay, and so we increased the signal by prolonging incubation times and using a colored product rather than direct measurement of NADH at 340 nm.
The total imprecision of the assay at the low qualitycontrol value (10 U/L) was an improvement over that reported (18.9%-63.1%) for a pool with a similar concentration in evaluation of commercially available CK-MB assays (7). The direct assay was rigorously evaluated after several months of routine laboratory use by six or 14 medical technologists at Barnes and Jewish Hospitals, respectively, using multiple lots of reagents. The higher imprecision at Jewish Hospital is probably due to the lesser automation, particularly in the washing step, and the greater number of people performing the assay. The accuracy of the assay was excellent as judged by the recovery, interference studies, and comparison with a twosite iminunoassay and agarose gel electrophoresis. We found a small (0.06%) influence of CK-BB with this assay configuration that we did not observe with our previous assay format (8). We are not certain whether this small crossreaction is actual or is instead ascribable to hybridization of our CK-BB preparation with heat-inactivated CK-MM. We did observe a sizable amount of hybridization between this preparation of CK-BB and purified CK-MM.
At any rate, even the 0.06% cross reactivity would not be a problem at the CK-BB concentrations that are present in serum.
In conclusion, our production and use of a monoclonal antibody specific for the MB isoenzyme of creatine kinase has allowed us to develop a simple, precise, and accurate assay for this important analyte. This assay has been in routine use at the chemistry laboratories at Barnes and Jewish Hospitals for eight months, with excellent results.
The final form of the assay was dictated by the requirements of these two laboratories. However, the basic method is flexible and can be modified depending on the type of equipment available and sensitivity required.
We expect that commercially available assays involving this antibody will soon be available.
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